Resignation of chief financial officer, joint company secretary and process agent, appointment of chief financial officer and appointment of process agent
Filed with HKEX · Stock code 9939 · · 2 pages · English
開拓藥業有限公司* KINTOR PHARMACEUTICAL LIMITED (Incorporated in the Cayman Islands with limited liability) (Stock code: 9939) RESIGNATION OF CHIEF FINANCIAL OFFICER, JOINT COMPANY SECRETARY AND PROCESS AGENT, APPOINTMENT OF CHIEF FINANCIAL OFFICER AND APPOINTMENT OF PROCESS AGENT RESIGNATION OF CHIEF FINANCIAL OFFICER, JOINT COMPANY SECRETARY AND PROCESS AGENT The board (the “Board”) of directors (“Direc
Kintor Pharmaceutical Ltd on 6ix
Earlier from Kintor Pharmaceutical
- Phase II Stage Of Pivotal Clinical Trial Of KX-826 Tincture 1.0% For The Treatment Of Male Adult Aga In China Reached Primary Endpoint
- Kintor Pharmaceutical: Pharma Announces Publication of Phase Ib/II Data from GT90001 and Nivolumab Combination Therapy for Advanced HCC in BMC Medicine
- Kintor Pharmaceutical: Pharma Announces the Approval of Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China
- Kintor Pharmaceutical: Pharma Announces 2023 Interim Results and Recent Business Highlights
- Kintor Pharmaceutical: Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China
Later from Kintor Pharmaceutical
- Interim report 2026
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement - receipt of notice of grant of invention patent for KT-939
Follow Kintor Pharmaceutical into a list and get an email when it puts out news.
Follow Kintor Pharmaceutical